Diagnosis of HHV-6 infection using real-time PCR method
Not Applicable
Completed
- Conditions
- Recipients of allogeneic stem cell transplantation, including bone marrow, peripheral blood, or cord blood transplantation
- Registration Number
- JPRN-UMIN000032349
- Lead Sponsor
- Department of Hematology, Oita University Hospital.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 0
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who didn't agree to participation and patients who were judged as inadequate to participate in this study by the opinion of the investigators.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Positive rate for HHV-6 DNA
- Secondary Outcome Measures
Name Time Method 1. Antiviral agents 2. Association between the results of blood HHV-6 DNA and the development of HHV-6 encephalitis 3. Sensitivity, specificity, positive predictive value, and negative predictive value of positive results for HHV-6 DNA for the diagnosis of HHV-6 encephalitis 4. Association between the results of HHV-6 DNA in cerebrospinal fluid and the development of HHV-6 encephalitis
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie HHV-6 reactivation in allogeneic stem cell transplant recipients using real-time PCR diagnostics?
How does real-time PCR compare to traditional methods for HHV-6 detection in hematopoietic stem cell transplantation settings?
Are there specific biomarkers that correlate with HHV-6 infection severity in allogeneic stem cell transplant patients using PCR-based diagnosis?
What are the potential adverse events associated with HHV-6 infection diagnosis via real-time PCR in post-transplant immunocompromised patients?
What is the role of HHV-6 in post-transplant complications and how does real-time PCR improve clinical management strategies?